Literature DB >> 25740187

[Neurosarcoidosis and paraneurosarcoidosis: new online registration of patients].

Mirjam Datema1, Martijn R Tannemaat, Marjolein Drent, Elske Hoitsma.   

Abstract

The clinical spectrum of neurosarcoidosis is highly diverse; virtually any neurological syndrome can present, depending upon granuloma localization. There are indications that neurosarcoidosis is insufficiently recognized as a separate clinical entity. In the absence of major prospective clinical trials, we launched a large national online registry of neurosarcoidosis patients in the Netherlands in June 2014 at www.neurosarcoidose.nl. When a patient with sarcoidosis presents with neurological symptoms that may compatible with sarcoidosis, it is important to locate sites of disease activity accessible for biopsy outside the nervous system. Small nerve fibre neuropathy is a common neurological complication of sarcoidosis. It is considered an epiphenomenon, and therefore classified as 'para-neurosarcoidosis'. Neurological symptoms causing disability are an indication for immunosuppressive therapy. There is increasing evidence for the effective treatment of refractory neurosarcoidosis using biologicals. Whether the intravenous administration of immunoglobulins or ARA290, an erythropoietin derivative with TNF-α-antagonistic and tissue-protective characteristics, is effective for small nerve fibre neuropathy in sarcoidosis is subject for study.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740187

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  Everyday cognitive failure in patients suffering from neurosarcoidosis.

Authors:  Mareye Voortman; Jolanda De Vries; Celine M R Hendriks; Marjon D P Elfferich; Petal A H M Wijnen; Marjolein Drent
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

2.  Determination of the smallest detectable change (SDC) and the minimal important difference (MID) for the Small Fiber Neuropathy Screening List (SFNSL) in sarcoidosis.

Authors:  Mareye Voortman; Emmylou Beekman; Marjolein Drent; Elske Hoitsma; Jolanda De Vries
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-09       Impact factor: 0.670

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.